The Cohesive Metastasis Phenotype in Human Prostate Cancer
Overview
Biophysics
Authors
Affiliations
A critical barrier for the successful prevention and treatment of recurrent prostate cancer is detection and eradication of metastatic and therapy-resistant disease. Despite the fall in diagnoses and mortality, the reported incidence of metastatic disease has increased 72% since 2004. Prostate cancer arises in cohesive groups as intraepithelial neoplasia, migrates through muscle and leaves the gland via perineural invasion for hematogenous dissemination. Current technological advances have shown cohesive-clusters of tumor (also known as microemboli) within the circulation. Circulating tumor cell (CTC) profiles are indicative of disseminated prostate cancer, and disseminated tumor cells (DTC) are found in cohesive-clusters, a phenotypic characteristic of both radiation- and drug-resistant tumors. Recent reports in cell biology and informatics, coupled with mass spectrometry, indicate that the integrin adhesome network provides an explanation for the biophysical ability of cohesive-clusters of tumor cells to invade thorough muscle and nerve microenvironments while maintaining adhesion-dependent therapeutic resistance. Targeting cohesive-clusters takes advantage of the known ability of extracellular matrix (ECM) adhesion to promote tumor cell survival and represents an approach that has the potential to avoid the progression to drug- and radiotherapy-resistance. In the following review we will examine the evidence for development and dissemination of cohesive-clusters in metastatic prostate cancer.
Prognostic Impact of H19/Cell Adhesion Molecules Circuitry on Prostate Cancer Biopsy.
Pecci V, Pierconti F, Carlino A, Pinto F, Gradilone U, De Martino S Biomedicines. 2024; 12(10).
PMID: 39457633 PMC: 11504315. DOI: 10.3390/biomedicines12102322.
Induction of Cell Death by DS1685 in Colorectal and Breast Cancers via SMAD4/TGF-Beta Activation.
Tae I, Lee J, Kang Y, Lee J, Park K, Yang H J Microbiol Biotechnol. 2024; 34(8):1698-1704.
PMID: 39113194 PMC: 11380517. DOI: 10.4014/jmb.2404.04055.
Target Volume Optimization for Localized Prostate Cancer.
Patel K, van der Heide U, Kerkmeijer L, Schoots I, Turkbey B, Citrin D Pract Radiat Oncol. 2024; 14(6):522-540.
PMID: 39019208 PMC: 11531394. DOI: 10.1016/j.prro.2024.06.006.
Pecci V, Troisi F, Aiello A, De Martino S, Carlino A, Fiorentino V Cancer Cell Int. 2024; 24(1):56.
PMID: 38317193 PMC: 10845766. DOI: 10.1186/s12935-024-03231-6.
Paxson A, Chang L, Gard J, Harryman W, Nelson C, Salmon S Front Cell Dev Biol. 2023; 11:1285372.
PMID: 38046670 PMC: 10690371. DOI: 10.3389/fcell.2023.1285372.